Catalyst
Slingshot members are tracking this event:
FDA approves Lucentis (ranibizumab injection) for myopic choroidal neovascularisation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RHHBY |
|
|
||||
Additional Information
This approval is based on the results of the Phase III RADIANCE study, which demonstrated that treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy (vPDT). At three months, average visual acuity gains for patients treated with Lucentis were more than 12 letters, compared to 1.4 letters for those treated with vPDT.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 06, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ranibizumab Injection, Lucentis, Myopic Choroidal Neovascularisation
